^
Association details:
| Biomarker: | FLT3-ITD mutation + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor, c-KIT inhibitor, FLT3 inhibitor, VEGFR-2 inhibitor, PKC inhibitor, PDGFR β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
Published date:
05/11/2023
Excerpt:
To evaluate the prognostic impact of the MRD status in pts 18-70 years with FLT3-ITD+ AML enrolled on the AMLSG16-10 trial (NCT01477606) combining intensive chemotherapy with midostaurin...Concurrent NPM1mut correlated with deeper molecular responses and higher rates of MRD-.
Secondary therapy:
Chemotherapy
Trial ID:
